

1 **Genomic Surveillance and Evolutionary Dynamics of Influenza A**

2 **Virus in Sri Lanka**

3 Tibutius Thanesh Pramanayagam Jayadas¹, Chandima Jeewandara¹, Bhagya Senadheera¹,
4 Heshan Kuruppu¹, Rivindu Wickramanayake¹, Farha Bary¹, Ananda Wijewickrama², Suranga
5 Manilgama², Manouri Gamage³, Nilanka Perera⁴, Graham S. Ogg⁵, Gathsaurie Neelika
6 Malavige^{1,5*}

7 ¹Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular
8 Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

9 ²National Institute of Infectious Diseases, Angoda, Sri Lanka.

10 ³Department of Paediatrics, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

11 ⁴Department of Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.

12 ⁵Translational Immune Discovery Unit, MRC Weatherall Institute of Molecular Medicine,
13 University of Oxford, Oxford, United Kingdom

14
15 *Prof. Neelika Malavige DPhil (Oxon), FRCP (Lond), FRCPath (UK)

16 Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular
17 Medicine,

18 Faculty of Medical Sciences, University of Sri Jayawardanapura, Sri Lanka.

19 Tel +94 (0) 772443193; Email: gathsaurie.malavige@ndm.ox.ac.uk

20

21 **Abstract**

22 **Background:** Influenza A has been named as a priority pathogen by the WHO due to the
23 potential to cause pandemics. Genomic sequencing of influenza strains is important to
24 understand the evolution of the influenza strains and also to select the appropriate influenza
25 vaccines to be used in the different influenza seasons in Sri Lanka. Therefore, we sought to
26 understand the molecular epidemiology of the influenza viruses in the Western Province of Sri
27 Lanka, including mutational analysis to investigate the evolutionary dynamics.

28 **Methodology:** A total of 349 individuals presenting with fever and respiratory symptoms were
29 enrolled in this study from November 2022 to May 2024. Nasopharyngeal and oropharyngeal
30 specimens were collected and screened using quantitative PCR to detect Influenza A, Influenza
31 B, and SARS-CoV-2. Subtyping and genomic sequencing was carried out on influenza A strains
32 using Oxford Nanopore Technology.

33 **Results:** Influenza A was detected in 49 (14 %) patients, influenza B in 20 (5.7%) and SARS-
34 CoV-2 in 41 (11.7%). Co-infections were observed in five participants. The phylogenetic
35 analysis assigned the H1N1 HA gene sequences within the 6B.1A.5a.2a clade. The HA gene of
36 the H1N1 sequences in 2023 were assigned as belonging to the subclades C.1, C.1.2, and C.1.8,
37 while the 2024 sequences were assigned to subclades C.1.8 and C.1.9. The H3N2 sequences
38 from 2023 were assigned to the 3C.2a1b.2a.2a.1b clade and subclade G.1.1.2, while the 2024
39 sequences were assigned to the 3C.2a1b.2a.2a.3a.1 clade and subclade J.2. The K54Q, A186T,
40 Q189E, E224A, R259K, K308R, I418V, and X215A amino acid substitutions were seen in the

41 H1N1 in the 2023 and 2024 sequences. The 2024 H1N1 sequences additionally exhibited further
42 substitutions, such as V47I, I96T, T120A, A139D, G339X, K156X, and T278S.

43 **Conclusion:** In this first study using genomic sequencing to characterize the influenza A strains
44 in Sri Lanka, which showed different influenza A viruses circulating in an 18-month period. As
45 the Sri Lankan strains also had certain mutations of unknown significance, it would be important
46 to continue detailed surveillance of the influenza strains in Sri Lanka to choose the most suitable
47 vaccines for the population and the timing of vaccine administration.

48

49 **Keywords:** Influenza A; SARS-CoV-2; vaccines; severe disease; genomic sequencing; clades;
50 subtypes; molecular epidemiology

51

52

53

54

55

56

57

58

59

60

61

62 **Introduction**

63 Seasonal influenza outbreaks are associated with significant morbidity and mortality, with
64 estimated cases 3.2 million cases of severe disease each year, globally [1]. Due to the potential
65 of influenza A strains causing pandemics, it has been included in the WHO pathogen
66 prioritization list published in 2024 [2]. Despite the availability of effective vaccines and
67 antivirals, the WHO estimates that 290,000 to 650,000 deaths occur annually due to this virus
68 [3]. Those at extremes of age, pregnant women, individuals with comorbidities and
69 immunocompromised individuals are at risk of developing severe disease and death [1]. Due to
70 the rapid evolution of the virus and emergence of avian influenza in certain regions in the world,
71 genomic surveillance of influenza strains is crucial to monitor the influenza strains that cause
72 outbreaks in different countries.

73

74 Influenza viruses belong to the Orthomyxoviridae family and are classified into four types: A, B,
75 C, and D. Among these types, the influenza A virus has been responsible for several major
76 pandemics in the past century, including the 1918 Spanish flu (H1N1), the 1957 Asian flu
77 (H2N2), and the 1968 Hong Kong flu (H3N2), all of which caused a significant global health
78 burden [4]. Influenza A viruses are categorized based on the properties of their surface
79 glycoproteins, hemagglutinin (HA) and neuraminidase (NA) [5]. The influenza A virus is
80 classified into different subtypes based on the HA and NA glycoproteins. There are 18 known
81 HA subtypes (H1 to H18) and 11 known NA subtypes (N1 to N11) [5]. The interplay of antigenic
82 shift and drift among these subtypes results in generation of multiple strains due to varied

83 combination of HA and NA subtypes [6]. Reassortment events, facilitated by natural reservoirs
84 such as swine, birds, and horses, contribute to the emergence of novel strains with pandemic
85 potential [6].

86 Globally, influenza A continues to exhibit seasonal patterns, with peaks typically occurring
87 during the winter months in temperate regions and outbreaks often coinciding with the monsoon
88 season in tropical and subtropical regions [7]. Although vaccination has been proven to be
89 effective in providing some protection against influenza, they need to be given annually due to
90 the changes in the circulating strains of the virus [8]. Therefore, the WHO Global Influenza
91 Program recommends an evidence-based approach by grouping countries with similar
92 seasonality patterns and virus antigenic characteristics into Influenza Vaccination Zones to
93 address specific country needs [9]. The WHO encourages countries to conduct local surveillance
94 to assess their seasonality patterns and circulating strains to facilitate the decision on selecting
95 Northern Hemisphere (NH) and Southern Hemisphere (SH) vaccines and to determine the timing
96 of vaccination campaigns [9].

97

98 Sri Lanka is a tropical country and influenza viruses circulate throughout the year, with two
99 peaks typically occurring during the rainy seasons which are from May to July and from
100 November to January[10]. As a part of the integrated SARS-CoV-2 and influenza surveillance
101 platform, limited number of samples are subjected to testing for the presence of influenza A and
102 SARS-CoV-2, which are then subjected to subtyping if influenza A is identified. However,
103 genomic sequencing is not carried out, which is important to identify the origin and evolution of
104 the influenza strains and also to select the appropriate influenza vaccines to be used in the
105 different influenza seasons in Sri Lanka. In this study, we carried out proceed to understand the

106 molecular epidemiology of the influenza viruses in the Western Province of Sri Lanka, including
107 mutational analysis to investigate the evolutionary dynamics.

108

109 **Methodology**

110 **Recruitment of patients and collection of samples**

111 Nasopharyngeal and oropharyngeal specimens were collected from both 349 adult and paediatric
112 patients presenting with an acute febrile illness with respiratory symptoms such as cough, sore
113 throat, and rhinorrhea. Patients were recruited from two tertiary care hospitals, which were the
114 National Institute of Infectious Disease and Colombo South Teaching Hospital, situated in the
115 Western Province of Sri Lanka, between November 2022 to May 2024. Patients with a duration
116 of illness of 7days were included in the study.

117

118 **Ethics approval**

119 Informed written consent was taken from all adult patients and in the case of paediatric patients,
120 informed written consent was obtained from their parents/guardian. Ethics approval was obtained
121 from the Ethics Review Committee, University of Sri Jayewardenepura.

122

123 **Screening for Respiratory Viruses Using Quantitative Polymerase Chain Reaction (qPCR)**

124 Viral RNA was extracted using Applied Biosystems™ MagMAX™ Viral/Pathogen Nucleic Acid
125 Isolation Kit. All the collected samples were screened for Influenza A, Influenza B, using

126 Respiratory Panel 1 qPCR Kit and when influenza A virus was detected it was also subtyped
127 using the Viasure, Spain (VS-RPA112L v.03). Concurrently, each sample was tested for the
128 presence of SARS-CoV-2 using TaqPath™ COVID-19 CE-IVD RT-PCR Kit (Thermo Fisher
129 Scientific, USA).

130

131 **Library preparation and sequencing of the influenza A virus**

132 All 49 samples that were identified as being infected with influenza A by qPCR were chosen for
133 ONT sequencing. The reaction mixture was prepared using 12.5 µL of Superscript III One-Step
134 PCR reaction buffer, 0.5 µL of SuperScript III RT/Platinum Taq Mix (Thermo Fisher Scientific,
135 USA), and primers (MBTuni-12 at 0.1 µM, MBTuni-12.4 at 0.1 µM, and MBTuni-13 at 0.2 µM).
136 Additionally, 2.5 µL of RNA template was added, and PCR grade water was used to attain a final
137 volume of 25 µL [11]. The PCR reactions were carried out with an initial incubation at 42 °C for
138 60 minutes, followed by denaturation at 94 °C for 2 minutes. This was succeeded by 5 cycles of
139 denaturation at 94 °C for 30 seconds, annealing at 45 °C for 30 seconds, and extension at 68 °C
140 for 3 minutes. Subsequently, 20 cycles were performed with denaturation at 94 °C for 30
141 seconds, annealing at 58 °C for 30 seconds, and extension at 68 °C for 3 minutes, concluding
142 with a final extension at 68 °C for 10 minutes.

143

144 Libraries for sequencing were generated from the amplified samples using the ONT Rapid
145 Barcoding Kit (SQK-RBK110.96), following the protocol version
146 RBK_9126_v110_revO_24Mar2021. The pooled barcoded MinION library was subsequently
147 loaded onto the MinION Mk1b sequencer from Oxford Nanopore Technologies, Oxford, United

148 Kingdom, equipped with an R9.4 flow cell. Real-time base calling was performed using
149 MinKNOW version 3.0.4 with the Guppy base calling software version 3.2.10.

150

151

152

153 **Generation of Consensus sequences (EPI2ME)**

154 Base calling was performed using the Guppy (version 6.5.7) with Fast model, 450 bps base
155 calling model. The resulting reads were analyzed using the wf-flu workflow. Samples that were
156 unclassified were excluded from further analysis. All samples that were successfully classified as
157 Archetypes were subsequently submitted to the GISAID database.

158

159

160 **Construction of phylogenetic trees**

161 We used HA and NA genes sequences with >90% coverage to create the phylogenetic trees.
162 Accession numbers included in the analysis are included in Supplementary Table.1. From 2021
163 to 2024 sequences from WHO South-East Asian region (100 simple random samples), WHO
164 global (100 random samples) and vaccine reference sequences in GISAID database was used to
165 construct the phylogenetics trees for HA gene and NA gene. Phylogenetic analyzes for all IAV
166 segments were performed. Sequence alignments were separately constructed for HA (H1 and H3
167 subtypes), NA (N1 and N2 subtypes). 222 sequences were included for analysis of H1, 209 for
168 H3, 224 for N1 and 210 sequences for N2.

169

170 Multiple sequence alignment was generated using MAFFT v.7.508 employing the FFT-NS-i
171 algorithm. Subsequently, this multiple sequence alignment was used to infer a Randomized
172 Accelerated Maximum Likelihood (RAxML) phylogenetic tree using RAxML (v.8.2.12) with
173 GTRGAMMA substitution model and bootstrap of 1000 replicates. The best-fit model
174 GTR+F+R5 was chosen using ModelFinder. Final visualizations of the phylogenetic tree were
175 done using R\ggtree, R\ape and R\ggstar packages (R version 4.1.2).

176 **Mutational analysis**

177 Mutation analysis was carried out for the sequenced samples, prior to the variant calling, by
178 removing the signal peptides in the H1 and H3 genes. To identify mutations in the H1N1
179 sequences, they were compared with the A/Wisconsin/588/2019 strain (EPI_ISL_19085699),
180 which is the 2021-2022 Northern Hemisphere vaccine strain for H1N1 [12]. To identify
181 mutations in the Sri Lankan H3N2 sequences, they were compared with the A/Darwin/6/2021
182 (EPI_ISL_1563628) which was the 2022 Southern Hemisphere vaccine strain for H3N2[13]. The
183 predicted position of the signal peptide in the sequences were identified with SignalP-5.0 tool.
184 Based on the analysis using this predictive model, we identified that the predicted position of the
185 signal peptide in the A/Wisconsin/588/2019 strain was in the positions in the amino acid
186 positions, 1 to 17 (likelihood ratio 0.797) and for the A/Darwin/6/2021, amino acid positions 1 to
187 16 (likelihood ratio, 0.6971). Mutations were analyzed and visualized with R packages (R
188 version 4.1.2) after removing the signal peptide region from the sequence of the protein.

189

190

191

192

193

194

195

196

197 **Results**

198 Of the 349 patients recruited in the study, 173 (49.5%) were males and 176 (50.4%) were
199 females and 205 (58.7%) were adults. Influenza A was detected in 49 (14 %) patients, influenza
200 B in 20 (5.7%) and SARS-CoV-2 in 41 (11.7%). Co-infections were observed in five
201 participants: four were co-infected with both Influenza A and B, and one individual was co-
202 infected with Influenza A and SARS-CoV-2. The age distribution of these infections in different
203 age groups is shown in figure 1. Notably, the highest incidence of influenza A (42.8%) and
204 influenza B (5.7%), was detected in children <10 years of age. In contrast, the highest incidence
205 of SARS-CoV-2 infection was seen in individuals > 60 years old, with 22.7% of the infections
206 been detected in this age group, while 6/66 (9.1%) were infected with influenza A.

207

208 **Influenza A virus subtyping, and seasonal patterns of infection**

209 Infection due to influenza A, influenza B and SARS-CoV-2 was detected during the study period
210 of November 2022 to May 2024. We paused the study during the months of July to October
211 2023, where very limited cases of respiratory infections were reported in both tertiary care
212 hospitals. Of the individuals who tested positive for Influenza A, 23 identified as H1N1, 18 as

213 H3N2, while 8 infections could not be classified. From December 2022 to February 2023, H1N1
214 was the predominant subtype of Influenza A (Supplementary Figure 1). However, a significant
215 shift occurred from early March 2023 to July 2023, with H3N2 becoming the dominant strain.
216 By December 2023, a resurgence of the H1N1 subtype was observed.

217

218

219 **Phylogenetic Analysis of H1N1 viruses**

220 Out of the 49 influenza A samples, 21 were successfully sequenced, comprising 17 H1N1
221 samples and 4 H3N2 samples. Based on sequence quality, 14 HA genes and all 17 NA genes
222 from the H1N1 viruses were included in the phylogenetic analysis, while 3 HA genes and 4 NA
223 genes from the H3N2 viruses were analyzed. The phylogenetic analysis assigned the H1N1 HA
224 gene sequences within the 6B.1A.5a.2a clade. The HA gene of the H1N1 sequences in 2023 were
225 assigned as belonging to the subclades C.1, C.1.2, and C.1.8, while the 2024 sequences were
226 assigned to subclades C.1.8 and C.1.9. Phylogenetic analysis of the H1N1 HA gene revealed that
227 the 2023 sequences were most closely related to strains from Bangladesh and Bangkok, whereas
228 the 2024 sequences were most similar to those from the Maldives (Figure 2).

229

230 The Sri Lankan H1N1 HA gene sequences and the A/Sydney/5/2021 Southern Hemisphere
231 vaccine strain (used in the 2023 Southern influenza vaccine) belong to clade 6B.1A.5a.2a.
232 Although A/Wisconsin/67/2022 and A/Victoria/4897/2022 from the Northern Hemisphere
233 vaccine reference are in the 6B.1A.5a.2a.1 clade, the Sri Lankan HA gene sequences from 2023
234 and 2024 were more closely related to these Northern Hemisphere H1N1 strains than to the

235 A/Sydney/5/2021 strain. The NA gene analysis showed that 2023 sequence showed close
236 resemblance to the sequences from England and 2024 NA gene sequences closely resembled
237 with sequences from Belgium and Bangladesh (Supplementary Figure 2).

238

239

240

241 **Phylogenetic Analysis of H3N2 viruses**

242 The H3N2 sequences from 2023 were assigned to the 3C.2a1b.2a.2a.1b clade and subclade
243 G.1.1.2, while the 2024 sequences were assigned to the 3C.2a1b.2a.2a.3a.1 clade and subclade
244 J.2. HA gene analysis revealed that the 2023 sequences were closely related to those from
245 Bangkok (Thailand), Cantabria (Spain), and England, whereas the 2024 sequences show
246 similarity to those from Belgium and Nakhon Pathom (Thailand) (Figure 3). The 2023 HA gene
247 sequence is more closely related to the A/Darwin/6/2021 vaccine strain, while the 2024 HA gene
248 sequence is more similar to A/Massachusetts/18/2022, both of which fall within the
249 3C.2a1b.2a.2a.3a.1 clade. NA gene analysis of the 2023 H3N2 samples indicated a close
250 relationship with sequences from Catalonia (Spain), Rhode Island (USA) and England, while the
251 2024 samples showed the similarity to sequences from France (Supplementary Figure 3).

252

253 **Mutation analysis**

254 The mutational analysis of the H1N1 hemagglutinin (HA) gene was carried out in reference to
255 the A/Wisconsin/588/2019 (H1N1) strain. Accordingly, we identified amino acid substitutions,

256 including K54Q, A186T, Q189E, E224A, R259K, K308R, I418V, and X215A across both the
257 2023 and 2024 sequences (Figure 4A). The 2024 H1N1 sequences additionally exhibited further
258 substitutions, such as V47I, I96T, T120A, A139D, G339X, K156X, and T278S. The positions of
259 these mutations and the function of these genes are shown in supplementary table 2. In the
260 neuraminidase (NA) gene, H1N1 sequences identified in 2023 and 2024 shared the X136Q and
261 V453M/V453T substitutions, with the 2024 sequences uniquely showing mutations at I264T,
262 E433X, and E433K (Figure 4B). In comparison to the A/Wisconsin/67/2022 vaccine reference
263 sequence, the HA gene of Sri Lankan H1N1 strains in 2023 and 2024, demonstrated substitutions
264 including S137P, R142K, E260D, A277T, and D356T. The 2024 sequences also presented
265 additional mutations, namely V47I, I96T, and T120A (Supplementary Figure 4A). In the NA
266 gene, the 2024 sequences revealed further substitutions at V13I, S200N, and L339S
267 (Supplementary Figure 4B).

268

269 In the hemagglutinin (HA) gene of H3N2, using A/Darwin/6/2021 (H3N2) as the reference, the
270 2023 sequence revealed several amino acid substitutions, including I200V, M193I, N160D,
271 E155G, R299K, D104G, and K276R. The I140K substitution was consistently observed across
272 all analyzed sequences. In contrast, the 2024 sequences exhibited additional substitutions such as
273 K189R, N49S, K276E, I260M, I223V, I192F, N122D, N96S, E50K, and G53N (Figure 4C). Due
274 to the E50K and I223V substitutions, our H3N2 strains in 2024, are most similar to the
275 A/Thailand/8/2022, subclade J). In comparison to the A/Massachusetts/18/2022 vaccine strain,
276 both the 2023 and 2024 sequences shared the K276E/K276R substitutions, while the 2024
277 sequence uniquely exhibited the L86X substitution (Supplementary Figure 4C). In the
278 neuraminidase (NA) gene, the 2023 sequence displayed the D346G substitution, whereas the

279 2024 sequence showed additional substitutions, including M51I, I469T, R400K, S44X, and
280 R150H (Figure 4D).

281

282

283

284

285 **Discussion**

286 In this study we have investigated the influenza strains circulating in the Western Province of Sri
287 Lanka from 2023 to mid-2024, providing detailed analysis of the circulating clades of Influenza
288 A. The frequency of both influenza A and influenza B was predominantly seen in children <10
289 years of age while SARS-CoV-2 infection was seen in adults >60 years of age. Many studies
290 have shown that individuals at extremes of age, including children, have shown to be vulnerable
291 to be hospitalized due to influenza [14]. However, in our cohort SARS-CoV-2 accounted for
292 most infections in those >60 years of age (22.7%) compared to 9.1% of infections due to
293 influenza A. Sri Lanka did not receive any COVID-19 vaccines as booster since 2022 [15] and
294 therefore, elderly individuals and those with comorbidities are at increased risk of hospitalization
295 due to COVID-19, possibly due to waning of immunity. In our cohort, 4 individuals had co-
296 infection with influenza A and B, while one patient had co-infection with influenza and SARS-
297 CoV-2. Co-infections with influenza A and B have been previously reported [16-18], and have
298 shown to associate with a worse disease outcome [17]. We also reported one patient with co-
299 infection with influenza and SAR-CoV-2, which has also previously been reported [19]. Due to

300 the limited sample size, we could not determine if co-infections were associated with worse
301 disease outcomes.

302
303 Seasonal influenza outbreaks usually coinciding with the monsoon season in tropical and
304 subtropical regions [7]. As reported in the Global Influenza Surveillance and Response System,
305 of the WHO, a similar pattern is observed in the Western Province, Sri Lanka, where there are
306 two influenza A seasons, which are from November to January and again from April to June [20].
307 During early 2023, the predominant influenza A subtype was H1N1, which was replaced by
308 H3N2 as the predominant subtype by June 2023. In 2024, again H1N1 became the predominant
309 subtype. These changes are consistent with the changes in the influenza A subtypes in India and
310 Nepal, but different to the changes in subtypes seen in Bangladesh, Thailand and Bhutan [20].

311
312 In our study, all H1N1 sequences from 2023 and 2024 were classified within the 6B.1A.5a.2a
313 clade. Our sequences, characterized by substitutions I418V and v47i, were placed within the C.1
314 subclade and its associated subclusters [21]. Similar H1N1 strains dominated in Southeast Asia,
315 the Middle East, Africa, Central America, and parts of Europe [21]. The 5a.2a.1 clade, which has
316 become more prevalent in the United States, Caribbean, Japan, and several European countries,
317 marked by mutations like P137S and K142R, has significantly diverged from the 5a.2a clade in
318 2023 [21]. This antigenic drift resulted in reduced effectiveness of the 5a.2a-based vaccine,
319 represented by the A/Sydney/5/2021 strain, leading the WHO to update the vaccine to target the
320 5a.2a.1 clade for the 2024 season, now represented by A/Wisconsin/67/2022 and
321 A/Victoria/4897/2022 [13]. Our influenza A H1N1 strains in 2024 had the additional mutations

322 I96T, T120A, A139D, G339X, K156X, and T278S. Although the positions and the function of
323 these genes which carried these mutations are known, the significance of these mutations in
324 relation to vaccine efficacy or virulence of the virus is not known. Therefore, it would be
325 important to continue surveillance to understand if the influenza vaccine containing the strains of
326 5a.2a.1 provides protection against both 5a.2a and 5a.2a.1 viruses, currently circulating in Sri
327 Lanka.

328

329 Our phylogenetic analysis of the A(H3N2) HA gene sequences revealed the circulation of the
330 3C.2a1b.2a.2a.1b clade in 2023 and the 3C.2a1b.2a.2a.3a.1 clade in 2024. In 2023, the
331 3C.2a1b.2a.2 subclade, characterized by mutations such as I140K and K276R, was the most
332 prevalence strain globally [20]. However, by 2024, the 3C.2a1b.2a.3 subclade, particularly the
333 2a.3a.1 lineage, emerged as the dominant strain [20, 21]. Our 2024 sequences aligned with the
334 .2a.3a.1 clade (clade J), marked by mutations such as K276E and V223I [21]. These changes led
335 to significant antigenic drift, reducing the efficacy of the A/Darwin/9/2021-based vaccine, which
336 was updated for 2024 including the A/Thailand/8/2022 and A/Massachusetts/18/ strains[21]. Our
337 2024 strains have additional mutations such as N122D and K276E. Although the effect of these
338 mutations on vaccine efficacy is not clear, it would be important to continue surveillance to
339 detect further emerging influenza strains.

340

341 In summary, in this study we have characterized the influenza A strains that circulated in Sri
342 Lanka over a period of 18 months. We found that all H1N1 sequences from 2023 and 2024 were
343 classified within the clade 6B.1A.5a.2a clade, while the H3N2 sequences in 2023 were assigned

344 to clade 3C.2a1b.2a.2a.1b and the 2024 strains to clade 3C.2a1b.2a.2a.3a.1. As the Sri Lankan
345 strains also had certain mutations of unknown significance, it would be important to continue
346 detailed surveillance of the influenza strains in Sri Lanka to choose the most suitable vaccines
347 for the population and the timing of vaccine administration.

348

349 **Acknowledgments**

350 We are grateful to the NIH, USA (grant number 5U01AI151788-02) and the UK Medical
351 Research Council for funding, also thankful to Asia Pathogen Genomic Initiative for providing
352 Influenza sequencing primers.

353 **References**

- 354 1. Paget J, Staadegaard L, Wang X, Li Y, van Pomeran T, van Summeren J, et al. Global and
355 national influenza-associated hospitalisation rates: Estimates for 40 countries and
356 administrative regions. *J Glob Health*. 2023;13:04003; doi: 10.7189/jogh.13.04003.
- 357 2. WHO: Pathogens Prioritization. A scientific framework for epidemic and pandemic
358 research preparedness. In.; 2024: 60.
- 359 3. WHO: Influenza (Seasonal). In.; 2023.
- 360 4. Piret J, Boivin G. Pandemics Throughout History. *Front Microbiol*. 2020;11:631736; doi:
361 10.3389/fmicb.2020.631736.
- 362 5. Uyeki TM, Hui DS, Zambon M, Wentworth DE, Monto AS. Influenza. *Lancet*.
363 2022;400(10353):693-706; doi: 10.1016/S0140-6736(22)00982-5.
- 364 6. Wu NC, Wilson IA. Influenza Hemagglutinin Structures and Antibody Recognition. *Cold
365 Spring Harb Perspect Med*. 2020;10(8); doi: 10.1101/cshperspect.a038778.
- 366 7. Tamerius JD, Shaman J, Alonso WJ, Bloom-Feshbach K, Uejio CK, Comrie A, et al.
367 Environmental predictors of seasonal influenza epidemics across temperate and tropical
368 climates. *PLoS pathogens*. 2013;9(3):e1003194; doi: 10.1371/journal.ppat.1003194.
- 369 8. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of
370 influenza vaccines: a systematic review and meta-analysis. *The Lancet infectious
371 diseases*. 2012;12(1):36-44; doi: 10.1016/S1473-3099(11)70295-X.
- 372 9. WHO. Global Influenza Programme. [https://www.who.int/teams/global-influenza-
373 programme/surveillance-and-monitoring/influenza-surveillance-outputs](https://www.who.int/teams/global-influenza-programme/surveillance-and-monitoring/influenza-surveillance-outputs) (2024). Accessed
374 15th August 2024 2024.

- 375 10. Rafeek RAM, Divarathna MVM, Noordeen F. History and current trends in influenza
376 virus infections with special reference to Sri Lanka. *Virusdisease*. 2017;28(3):225-32;
377 doi: 10.1007/s13337-017-0390-8.
- 378 11. Zhou B, Donnelly ME, Scholes DT, St George K, Hatta M, Kawaoka Y, et al. Single-
379 reaction genomic amplification accelerates sequencing and vaccine production for
380 classical and Swine origin human influenza A viruses. *Journal of virology*.
381 2009;83(19):10309-13; doi: 10.1128/JVI.01109-09.
- 382 12. WHO: Recommendations announced for influenza vaccine composition for the 2022-
383 2023 northern hemisphere influenza season. In.; 2022.
- 384 13. WHO: Recommended composition of influenza virus vaccines for use in the 2024
385 southern hemisphere influenza season. In.; 2022.
- 386 14. Gilca R, Amini R, Carazo S, Doggui R, Frenette C, Boivin G, et al. The Changing
387 Landscape of Respiratory Viruses Contributing to Hospitalizations in Quebec, Canada:
388 Results From an Active Hospital-Based Surveillance Study. *JMIR Public Health Surveill*.
389 2024;10:e40792; doi: 10.2196/40792.
- 390 15. Hannah Ritchie EO-O, Diana Beltekian, Edouard Mathieu, Joe Hasell, Bobbie
391 Macdonald, Charlie Giattino, Cameron Appel and Max Roser. Coronavirus (COVID-19)
392 Vaccinations. <https://ourworldindata.org/covid-vaccinations> (2024). Accessed.
- 393 16. He J, Hou S, Chen Y, Yu JL, Chen QQ, He L, et al. The Epidemiological Pattern and Co-
394 infection of Influenza A and B by Surveillance Network From 2009 to 2014 in Anhui
395 Province, China. *Front Public Health*. 2022;10:825645; doi: 10.3389/fpubh.2022.825645.

- 396 17. Gregianini TS, Varella IRS, Fisch P, Martins LG, Veiga ABG. Dual and Triple Infections
397 With Influenza A and B Viruses: A Case-Control Study in Southern Brazil. *The Journal of*
398 *infectious diseases*. 2019;220(6):961-8; doi: 10.1093/infdis/jiz221.
- 399 18. Miron VD, Banica L, Sandulescu O, Paraschiv S, Surleac M, Florea D, et al. Clinical and
400 molecular epidemiology of influenza viruses from Romanian patients hospitalized during
401 the 2019/20 season. *PloS one*. 2021;16(11):e0258798; doi:
402 10.1371/journal.pone.0258798.
- 403 19. Dadashi M, Khaleghnejad S, Abedi Elkhichi P, Goudarzi M, Goudarzi H, Taghavi A, et
404 al. COVID-19 and Influenza Co-infection: A Systematic Review and Meta-Analysis.
405 *Front Med (Lausanne)*. 2021;8:681469; doi: 10.3389/fmed.2021.681469.
- 406 20. WHO. Global Influenza Surveillance and Response System (GISRS).
407 <https://www.who.int/initiatives/global-influenza-surveillance-and-response-system>
408 (2024). Accessed 15th August 2024 2024.
- 409 21. WHO: Influenza virus characterization: summary report, Europe, March 2024. In. Edited
410 by Control CWROfEaSECfDPa; 2024: 29.

411

412

413

414

415

416

417

418 **Figure legends**

419 **Figure 1:** Distribution of influenza A, influenza B, and SARS-CoV-2 infections across different
420 age groups among recruited participants

421

422 **Figure 2: Phylogenetic tree of the H1N1 HA gene.** The phylogenetic tree was generated with
423 the Sri Lankan H1N1 sequences (n=14) in comparison to the global H1N1 strains. All the Sri
424 Lankan were assigned to clade 6B.1A.5a.2a. The H1N1 Sri Lankan sequence clusters are shaded
425 in green, orange and grey shades, while the reference sequences are highlighted in green.

426

427 **Figure 3: Phylogenetic tree of the H3N2 HA gene.** The phylogenetic tree was generated with
428 the Sri Lankan H3N2 sequences (n=3) in comparison to the global H1N1 strains. The 2023
429 sequence was assigned to the 3C.2a1b.2a.2a.1b clade, while the 2024 sequences were assigned to
430 the 3C.2a1b.2a.2a.3a.1 clade. The H1N1 Sri Lankan sequence clusters are shaded in green,
431 orange and grey shades, while the reference sequences are highlighted in green.


432

433 **Figure 4: Heatmap of amino acid substitutions in hemagglutinin (HA) and neuraminidase**
434 **(NA) genes of influenza A H1N1 and H3N2 viruses.** (Panels A and B show mutations in the
435 HA and NA genes of H1N1, respectively, while panels C and D display mutations in the HA and
436 NA genes of H3N2. Each row represents an individual virus sequence, identified by its GISAID
437 EPI_ISL accession number, and each column represents a specific amino acid position where


438 mutations have occurred. The presence of a mutation is indicated by a blue square, and the
439 absence by a white square).

440

441



Hemagglutinin gene of H1N1 Phylogenetic Tree



Hemagglutinin gene of H3N2 Phylogenetic Tree

